Session

IBD (Posters)

SZN1326, A WNT AGONIST, WAS SUPERIOR TO ANTI-IL12/23P40 AND ANTI-TNF-A ANTIBODIES IN RESTORING EPITHELIAL INTEGRITY AND MITIGATING COLITIS IN A CHRONIC DSS MODEL
SZN1326, A WNT AGONIST, WAS SUPERIOR TO ANTI-IL12/23P40 AND ANTI-TNF-A ANTIBODIES IN RESTORING EPITHELIAL INTEGRITY AND MITIGATING COLITIS IN A CHRONIC DSS MODEL

ATTITUDE OF PATIENTS WITH IBD TOWARD COVID-19 VACCINE IN SAUDI ARABIA
ATTITUDE OF PATIENTS WITH IBD TOWARD COVID-19 VACCINE IN SAUDI ARABIA

A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLINDED, CROSS OVER FODMAP PROVOCATION IN PATIENTS WITH ULCERATIVE COLITIS AND IRRITABLE BOWEL SYNDROME ON A LOW FODMAP DIET
A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLINDED, CROSS OVER FODMAP PROVOCATION IN PATIENTS WITH ULCERATIVE COLITIS AND IRRITABLE BOWEL SYNDROME ON A LOW FODMAP DIET

PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET
PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET

ASSESSMENT OF SARCOPENIA AND NUTRITIONAL STATUS IN A COHORT OF PATIENTS WITH CROHN'S DISEASE
ASSESSMENT OF SARCOPENIA AND NUTRITIONAL STATUS IN A COHORT OF PATIENTS WITH CROHN'S DISEASE

NON-INVASIVE BIOMARKERS OF TYPE III COLLAGEN CROSS-LINKING REFLECT FIBROLYSIS IN CROHN'S DISEASE PATIENTS WITH A NON-STRICTURING AND NON-PENETRATING DISEASE BEHAVIOUR
NON-INVASIVE BIOMARKERS OF TYPE III COLLAGEN CROSS-LINKING REFLECT FIBROLYSIS IN CROHN'S DISEASE PATIENTS WITH A NON-STRICTURING AND NON-PENETRATING DISEASE BEHAVIOUR

ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASE AND SPONDYLOARTHROPATHIES: FINDINGS FROM A NATIONWIDE STUDY IN SWEDEN
ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASE AND SPONDYLOARTHROPATHIES: FINDINGS FROM A NATIONWIDE STUDY IN SWEDEN

IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS) STUDIES
LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS) STUDIES

THERAPEUTIC DRUG MONITORING: PERFORMANCE OF THE FIRST LATERAL FLOW-BASED POINT OF CARE TEST FOR THE QUANTIFICATION OF INFLIXIMAB IN A FINGER PRICK
THERAPEUTIC DRUG MONITORING: PERFORMANCE OF THE FIRST LATERAL FLOW-BASED POINT OF CARE TEST FOR THE QUANTIFICATION OF INFLIXIMAB IN A FINGER PRICK

CORRELATION OF THE FIRST LATERAL FLOW-BASED POINT OF CARE TEST TO QUANTIFY INFLIXIMAB AND ANTI-INFLIXIMAB ANTIBODIES IN A FINGER PRICK SAMPLE WITH THE REFERENCE ELISA TECHNIQUE
CORRELATION OF THE FIRST LATERAL FLOW-BASED POINT OF CARE TEST TO QUANTIFY INFLIXIMAB AND ANTI-INFLIXIMAB ANTIBODIES IN A FINGER PRICK SAMPLE WITH THE REFERENCE ELISA TECHNIQUE

SAFETY OF CONCURRENT ADMINISTRATION OF OZANIMOD AND SEROTONERGIC ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS
SAFETY OF CONCURRENT ADMINISTRATION OF OZANIMOD AND SEROTONERGIC ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS

THE INFLAMMATORY BOWEL DISEASE - DISK TOOL FOR ASSESSING DISABILITY IN INFLAMMATORY BOWEL DISEASE PATIENTS: VALIDATION OF THE GREEK VERSION
THE INFLAMMATORY BOWEL DISEASE - DISK TOOL FOR ASSESSING DISABILITY IN INFLAMMATORY BOWEL DISEASE PATIENTS: VALIDATION OF THE GREEK VERSION

MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN'S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY
MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN'S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY

EFFICACY OF SUBCUTANEOUS INFLIXIMAB IN PERIANAL CROHN'S DISEASE
EFFICACY OF SUBCUTANEOUS INFLIXIMAB IN PERIANAL CROHN'S DISEASE

PREVALENCE AND RISK FACTORS FOR MALIGNANCY IN INFLAMMATORY BOWEL DISEASE
PREVALENCE AND RISK FACTORS FOR MALIGNANCY IN INFLAMMATORY BOWEL DISEASE

CHARACTERISTICS AND REAL WORLD TREATMENT HISTORY OF PATIENTS TREATED WITH TOFACITINIB FOR ULCERATIVE COLITIS IN EUROPE
CHARACTERISTICS AND REAL WORLD TREATMENT HISTORY OF PATIENTS TREATED WITH TOFACITINIB FOR ULCERATIVE COLITIS IN EUROPE

INCIDENCE, CLINICAL PRESENTATION, AND SEVERITY OF SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN THE "SECOND AND THE THIRD WAVE" OF INFECTION
INCIDENCE, CLINICAL PRESENTATION, AND SEVERITY OF SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN THE "SECOND AND THE THIRD WAVE" OF INFECTION

MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

THE CHANGING TRENDS SEEN WITH SURGERY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE OVER A 25 YEAR REVIEW PERIOD
THE CHANGING TRENDS SEEN WITH SURGERY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE OVER A 25 YEAR REVIEW PERIOD

Item 161 - 180 / 568
1 2 3 4 5 6 7 8
9
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29